Ralinepag - Arena Pharmaceuticals

Drug Profile

Ralinepag - Arena Pharmaceuticals

Alternative Names: APD-811

Latest Information Update: 10 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arena Pharmaceuticals
  • Class Acetic acids; Antihypertensives; Carbamates; Chlorobenzenes; Small molecules
  • Mechanism of Action Epoprostenol receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pulmonary arterial hypertension

Most Recent Events

  • 06 Aug 2018 Phase-III clinical trials in Pulmonary arterial hypertension (PO)
  • 06 Aug 2018 Arena Pharmaceuticals plans the ADVANCE CAPACITY and ADVANCE ENDURANCE phase III trials for Pulmonary arterial hypertension (PO), in Q4 of 2018 and Q1 of 2019, respectively
  • 05 Dec 2017 Ralinepag licensed to Everest Medicines in China, Taiwan, Hong Kong, Macau, and South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top